Skip to main content
Anna Berkenblit, MD, Oncology, Cambridge, MA

AnnaBerkenblitMD

Oncology • Cambridge, MA

Hematologic Oncology

Chief Medical Officer and Vice President of ImmunoGen, Inc

Join to view full profile

Dr. Berkenblit is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Berkenblit's full profile

Already have an account?

Education & Training

  • Harvard Medical School
    Harvard Medical SchoolClass of 1996

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1998 - 2024

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
    ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid LeukemiaDecember 9th, 2022
  • ImmunoGen Needs to Make the Most of Its First-Mover Opportunity
    ImmunoGen Needs to Make the Most of Its First-Mover OpportunityNovember 30th, 2022
  • ImmunoGen ELAHERE Wins Accelerated FDA Approval for Ovarian Cancer
    ImmunoGen ELAHERE Wins Accelerated FDA Approval for Ovarian CancerNovember 16th, 2022
  • Join now to see all

Professional Memberships

Dr. Anna Berkenblit, Dr. Anna Berkenblit, MD, Dr. A Berkenblit